Seborrheic Dermatitis

  • Danya Reich
  • Corinna Eleni Psomadakis
  • Bobby Buka


A 42-year-old female patient attended the Primary Care clinic to receive treatment for a recurrent facial rash. She had previously been diagnosed with psoriasis. The appearance and distribution of the erythematous, flaking rash at her visit was consistent with seborrheic dermatitis; however, the two diseases exist on a spectrum, with mild psoriasis and seborrheic dermatitis sometimes being clinically indistinguishable. Seborrheic dermatitis is a common, chronic skin condition whose exact pathogenesis is not known. It is most likely a multifactorial inflammatory process, at least partially triggered by irritating metabolites of the Malassezia yeast. Immunocompromised hosts are especially susceptible to seborrheic dermatitis. The condition manifests as a pruritic, erythematous, flaking rash with a greasy appearance, and primarily affects the scalp, face, and retroauricular area. Topical antifungals and corticosteroids are the primary treatment modalities for seborrheic dermatitis. The chronicity of the condition often warrants long-term maintenance therapy, which includes over-the-counter shampoos with pyrithione zinc or selenium sulfide, and intermittent mild corticosteroid application. During flares, lesions may be more susceptible to superficial infections as the skin barrier becomes compromised.


Seborrhea Seborrheic dermatitis Seborrheic eczema Sebopsoriasis Dandruff Scalp Flaking Scale Psoriasis Inflammation Fungal infection Cradle cap Corticosteroid Antifungal 


  1. 1.
    Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):343–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18(1):13–26.CrossRefPubMedGoogle Scholar
  3. 3.
    Wolff K, Johnson RA, Suurmond D. Chapter 2, Eczema/dermatitis. In: Fitzpatrick’s color atlas & synopsis of clinical dermatology. 5th ed. New York: McGraw-Hill; 2005. p. 49–50.Google Scholar
  4. 4.
    Kastarinen H, Oksanen T, Okokon EO, Kiviniemi VV, Airola K, Jyrkkä J, Oravilahti T, Rannanheimo PK, Verbeek JH. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp (Review). Cochrane Database Syst Rev. 2014;5, CD009446. doi: 10.1002/14651858.CD009446.pub2.Google Scholar
  5. 5.
    Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, Sidou F, Faergemann J. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Br J Dermtol. 2011;65(1):171–6.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Open Access This chapter is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Authors and Affiliations

  • Danya Reich
    • 1
  • Corinna Eleni Psomadakis
    • 2
  • Bobby Buka
    • 3
  1. 1.Department of Family MedicineMount Sinai School of Medicine Attending Mount Sinai Doctors/Beth Israel Medical Group-WilliamsburgBrooklynUSA
  2. 2.School of Medicine Imperial College LondonLondonUK
  3. 3.Department of DermatologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations